Atara Biotherapeutics, Inc. cash flow to debt ratio of -96.48% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Atara Biotherapeutics, Inc.'s free cash flow has increased -26.13% from $-68.96M last year to $-50.94M, signaling increasing performance

Atara Biotherapeutics, Inc.'s debt to equity ratio is -0.27, signaling that the company spent its equity and risk bankruptcy.

Atara Biotherapeutics, Inc.'s debt to equity ratio is -0.27, signaling that the company spent its equity and risk bankruptcy.

Atara Biotherapeutics, Inc. has a net debt to EBITDA ratio of 1.15x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

Atara Biotherapeutics, Inc.'s interest coverage ratio is -1.75, which means that the company struggles to meet interest obligations, signaling financial risk.

Atara Biotherapeutics, Inc.'s profit margin has increased (-38.23%) in the last year from -66.23% to -40.91%, signaling increasing performance

Atara Biotherapeutics, Inc.'s short-term liabilities of $14.92M exceed its short-term assets of $12.21M, signaling financial risk

Atara Biotherapeutics, Inc.'s return on assets of -47.34% is lower than the 5.00% threshold, indicating inefficient asset utilization

Atara Biotherapeutics, Inc.'s return on equity of 25.68%, is higher than 15.00%, indicating good performance

Atara Biotherapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Atara Biotherapeutics, Inc. had positive net income in only 1.00 out of 5 years, indicating unstable earnings

Atara Biotherapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Atara Biotherapeutics, Inc. has negative free cash flow, indicating cash burn

Atara Biotherapeutics, Inc.'s yearly earnings has increased -138.28% since last year from $-85.40M to $32.69M, signaling increasing performance

Atara Biotherapeutics, Inc.'s yearly revenue has decreased -6.33% since last year from $128.94M to $120.77M, signaling decreasing performance

ROIC -41.06% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Atara Biotherapeutics, Inc.'s 3-year revenue CAGR of 23.85% is positive, indicating growing revenue over the past 3 years

Atara Biotherapeutics, Inc. had revenue growth in 3.00 out of 5 years, indicating consistent revenue performance

Atara Biotherapeutics, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Atara Biotherapeutics, Inc. has insufficient data to evaluate this check.

Atara Biotherapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Atara Biotherapeutics, Inc. is undervalued relative to its fair value price of 37.73 based on EBITDA multiple model

Atara Biotherapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Atara Biotherapeutics, Inc. has insufficient data to evaluate this check.

Atara Biotherapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Atara Biotherapeutics, Inc. has negative shareholder equity; price-to-book is not meaningful and the check fails

Atara Biotherapeutics, Inc. has a price-to-sales ratio of 4.09x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue